{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:56:42Z","timestamp":1793332602953,"version":"4.5.0"},"reference-count":139,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,29]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Sarcomas are rare malignancies of mesenchymal origin, characterized by significant biological and clinical heterogeneity. Many subtypes demonstrate limited sensitivity to standard systemic treatments, including immune checkpoint inhibitors. Cell therapy has emerged as a promising strategy, with the potential of durable clinical responses seen with genetically-engineered T-cell receptor T-cell therapies (TCR-T) such as those targeting the cancer-testis antigen MAGE-A4 in synovial sarcoma, leading to the US Food and Drug Administration approval of afamitresgene autoleucel in 2024. This constituted only the second approval of a cell therapy in a solid tumor following lifileucel in melanoma and demonstrated the potential of cell therapies in sarcomas. This review provides the current landscape and growing potential of cell therapies in sarcomas, including TCR-T, chimeric antigen receptor-T cells, tumor-infiltrating lymphocytes, natural killer (NK) cells, and mesenchymal stromal cells. However, the broader application of these therapies is hindered by the lack of targetable sarcoma-restricted immunogenic epitopes, spatiotemporal intratumoral heterogeneity, and a profoundly immunosuppressive tumor microenvironment that impedes effector-cell trafficking, expansion and persistence. While cell therapies hold promise for integration into precision medicine approaches for sarcomas, their successful implementation will require careful evaluation of clinical feasibility, logistical considerations and cost-effectiveness to optimize patient outcomes.<\/jats:p>","DOI":"10.1136\/jitc-2025-013396","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:40:16Z","timestamp":1768232416000},"page":"e013396","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Cell therapy in sarcoma: current landscape and future directions"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03967223","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03721068","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03618381","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04052334","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03935893","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03941262","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06117878","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05634369","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06083883","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04995003","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03635632","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05312411","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06474676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06083883","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-0426","authenticated-orcid":false,"given":"Taha Koray","family":"Sahin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Germetaki","sequence":"additional","affiliation":[{"name":"Sarcoma Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Akin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Dizdar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[{"name":"Advanced Immunotherapy and Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, England, UK"},{"name":"Division of Cancer Sciences, The University of Manchester Faculty of Biology Medicine and Health, Manchester, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Connolly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"ProCan, Children\u2019s Medical Research Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-9218","authenticated-orcid":false,"given":"Kok Haw Jonathan","family":"Lim","sequence":"additional","affiliation":[{"name":"Advanced Immunotherapy and Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, England, UK"},{"name":"Division of Cancer Sciences, The University of Manchester Faculty of Biology Medicine and Health, Manchester, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2026011207400984000_14.1.e013396.1","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-213"},{"key":"2026011207400984000_14.1.e013396.2","unstructured":"Fletcher C , Bridge JA , Hogendoorn PCW , et al . WHO Classification of tumours of soft tissue and bone: WHO classification of tumours. 5. World Health Organization, 2013."},{"key":"2026011207400984000_14.1.e013396.3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0079"},{"key":"2026011207400984000_14.1.e013396.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1995"},{"key":"2026011207400984000_14.1.e013396.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.006"},{"key":"2026011207400984000_14.1.e013396.6","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Puerto D , Cicala CM , Valverde C , et al . Emerging treatments for sarcoma: from 2024 onward. Expert Opin Emerg Drugs 2025;1\u201318. doi:10.1080\/14728214.2025.2460525","DOI":"10.1080\/14728214.2025.2460525"},{"key":"2026011207400984000_14.1.e013396.7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081685","article-title":"Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives","volume":"10","author":"Z\u00f6llner","year":"2021","journal-title":"J Clin Med"},{"key":"2026011207400984000_14.1.e013396.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30622-8"},{"key":"2026011207400984000_14.1.e013396.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70063-4"},{"key":"2026011207400984000_14.1.e013396.10","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432234","article-title":"Immunotherapy in Sarcoma: Current Data and Promising Strategies","volume":"44","author":"Wood","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026011207400984000_14.1.e013396.11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1069963","article-title":"Exploring the landscape of immunotherapy approaches in sarcomas","volume":"12","author":"Pilavaki","year":"2022","journal-title":"Front Oncol"},{"key":"2026011207400984000_14.1.e013396.12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.tips.2024.10.016","article-title":"Advances in cell therapy: progress and challenges in hematological and solid tumors","volume":"45","author":"D\u2019Avanzo","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"2026011207400984000_14.1.e013396.13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jcp.30575","article-title":"Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities","volume":"237","author":"Bashash","year":"2022","journal-title":"J Cell Physiol"},{"key":"2026011207400984000_14.1.e013396.14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245760","article-title":"Immune Cells in the Tumor Microenvironment of Soft Tissue Sarcomas","volume":"15","author":"Jumaniyazova","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026011207400984000_14.1.e013396.15","doi-asserted-by":"crossref","first-page":"1507870","DOI":"10.3389\/fimmu.2025.1507870","article-title":"Emerging immunotherapy and tumor microenvironment for advanced sarcoma: a comprehensive review","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"2026011207400984000_14.1.e013396.16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"2026011207400984000_14.1.e013396.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3416"},{"key":"2026011207400984000_14.1.e013396.18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.14348\/molcells.2023.0079","article-title":"Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities","volume":"46","author":"Jeong","year":"2023","journal-title":"Mol Cells"},{"key":"2026011207400984000_14.1.e013396.19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s43018-024-00743-y","article-title":"Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy","volume":"5","author":"Subramanian","year":"2024","journal-title":"Nat Cancer"},{"key":"2026011207400984000_14.1.e013396.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8"},{"key":"2026011207400984000_14.1.e013396.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01821-3"},{"key":"2026011207400984000_14.1.e013396.22","doi-asserted-by":"crossref","first-page":"S1434","DOI":"10.1016\/j.annonc.2025.08.3298","article-title":"2687MO CONgRAtS: A randomized phase II study of nivolumab\u00b1relatlimab in patients with TLS-positive soft-tissue sarcomas","volume":"36","author":"Peyraud","year":"2025","journal-title":"Ann Oncol"},{"key":"2026011207400984000_14.1.e013396.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110977"},{"key":"2026011207400984000_14.1.e013396.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31911"},{"key":"2026011207400984000_14.1.e013396.25","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1200\/JCO.2016.34.15_suppl.11008","article-title":"Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity","volume":"34","author":"Toulmonde","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026011207400984000_14.1.e013396.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-025-01514-9","article-title":"SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics","volume":"17","author":"Testa","year":"2025","journal-title":"Genome Med"},{"key":"2026011207400984000_14.1.e013396.27","doi-asserted-by":"crossref","first-page":"756029","DOI":"10.3389\/fmed.2021.756029","article-title":"Cell Therapy: Types, Regulation, and Clinical Benefits","volume":"8","author":"El-Kadiry","year":"2021","journal-title":"Front Med"},{"key":"2026011207400984000_14.1.e013396.28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/intimm\/dxad051","article-title":"Trends in cell medicine: from autologous cells to allogeneic universal-use cells for adoptive T-cell therapies","volume":"36","author":"Kawamoto","year":"2024","journal-title":"Int Immunol"},{"key":"2026011207400984000_14.1.e013396.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"2026011207400984000_14.1.e013396.30","doi-asserted-by":"crossref","unstructured":"Ayala Ceja M , Khericha M , Harris CM , et al . CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med 2024;221. doi:10.1084\/jem.20230903","DOI":"10.1084\/jem.20230903"},{"key":"2026011207400984000_14.1.e013396.31","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04292-3"},{"key":"2026011207400984000_14.1.e013396.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"2026011207400984000_14.1.e013396.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2035"},{"key":"2026011207400984000_14.1.e013396.34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic malignancies: achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026011207400984000_14.1.e013396.35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40291-024-00708-y","article-title":"Lifileucel: First Approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"2026011207400984000_14.1.e013396.36","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1158\/1078-0432.CCR-25-0595","article-title":"FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy","volume":"31","author":"Barnett","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026011207400984000_14.1.e013396.37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front Immunol"},{"key":"2026011207400984000_14.1.e013396.38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"2026011207400984000_14.1.e013396.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00809-z"},{"key":"2026011207400984000_14.1.e013396.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.02.001"},{"key":"2026011207400984000_14.1.e013396.41","first-page":"21","article-title":"Adoptive Cell Therapy for Sarcoma","volume":"7","author":"Mata","year":"2015","journal-title":"Immunotherapy (Los Angel)"},{"key":"2026011207400984000_14.1.e013396.42","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70020","article-title":"NY\u2010ESO\u20101 antigen: A promising frontier in cancer immunotherapy","volume":"14","author":"Alsalloum","year":"2024","journal-title":"Clinical & Translational Med"},{"key":"2026011207400984000_14.1.e013396.43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","volume":"61","author":"Iura","year":"2017","journal-title":"Hum Pathol (N Y)"},{"key":"2026011207400984000_14.1.e013396.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2537"},{"key":"2026011207400984000_14.1.e013396.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708"},{"key":"2026011207400984000_14.1.e013396.46","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1002\/cam4.3039","article-title":"Clinical outcomes of patients with advanced synovial sarcoma or myxoid\/round cell liposarcoma treated at major cancer centers in the United States","volume":"9","author":"Pollack","year":"2020","journal-title":"Cancer Med"},{"key":"2026011207400984000_14.1.e013396.47","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1417"},{"key":"2026011207400984000_14.1.e013396.48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.2500","article-title":"Lete-cel in patients with synovial sarcoma or myxoid\/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial","volume":"42","author":"D\u2019Angelo","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026011207400984000_14.1.e013396.49","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO-24-01466","article-title":"Letetresgene Autoleucel in Advanced\/Metastatic Myxoid\/Round Cell Liposarcoma","volume":"43","author":"D\u2019Angelo","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026011207400984000_14.1.e013396.50","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026011207400984000_14.1.e013396.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02128-z"},{"key":"2026011207400984000_14.1.e013396.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2"},{"key":"2026011207400984000_14.1.e013396.53","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0762-2","article-title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","volume":"7","author":"Ramachandran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026011207400984000_14.1.e013396.54","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2018.36.15_suppl.3005","article-title":"T cells in advanced myxoid\/round cell liposarcoma","volume":"36","author":"D\u2019Angelo","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026011207400984000_14.1.e013396.55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32491-x","article-title":"Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma","volume":"13","author":"Gyurdieva","year":"2022","journal-title":"Nat Commun"},{"key":"2026011207400984000_14.1.e013396.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"2026011207400984000_14.1.e013396.57","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","article-title":"Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial","volume":"31","author":"Wermke","year":"2025","journal-title":"Nat Med"},{"key":"2026011207400984000_14.1.e013396.58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front Immunol"},{"key":"2026011207400984000_14.1.e013396.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0470-3"},{"key":"2026011207400984000_14.1.e013396.60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00642"},{"key":"2026011207400984000_14.1.e013396.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026011207400984000_14.1.e013396.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2026011207400984000_14.1.e013396.63","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0"},{"key":"2026011207400984000_14.1.e013396.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406526"},{"key":"2026011207400984000_14.1.e013396.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"2026011207400984000_14.1.e013396.66","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00933-8"},{"key":"2026011207400984000_14.1.e013396.67","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int"},{"key":"2026011207400984000_14.1.e013396.68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225"},{"key":"2026011207400984000_14.1.e013396.69","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2019-lb-068"},{"key":"2026011207400984000_14.1.e013396.70","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"2026011207400984000_14.1.e013396.71","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"key":"2026011207400984000_14.1.e013396.72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859"},{"key":"2026011207400984000_14.1.e013396.73","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ejso.2006.01.012","article-title":"Expression of HER1\/EGFR protein in human soft tissue sarcomas","volume":"32","author":"Yang","year":"2006","journal-title":"European Journal of Surgical Oncology (EJSO)"},{"key":"2026011207400984000_14.1.e013396.74","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2541","article-title":"STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent\/refractory solid tumors in children and young adults","volume":"40","author":"Albert","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026011207400984000_14.1.e013396.75","doi-asserted-by":"crossref","first-page":"1150765","DOI":"10.3389\/fonc.2023.1150765","article-title":"New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas","volume":"13","author":"Seong","year":"2023","journal-title":"Front Oncol"},{"key":"2026011207400984000_14.1.e013396.76","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-13061-4","article-title":"B7-H3 is widely expressed in soft tissue sarcomas","volume":"24","author":"Lynch","year":"2024","journal-title":"BMC Cancer"},{"key":"2026011207400984000_14.1.e013396.77","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13287-022-02819-x","article-title":"Hurdles to breakthrough in CAR T cell therapy of solid tumors","volume":"13","author":"Marofi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"2026011207400984000_14.1.e013396.78","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00704-3"},{"key":"2026011207400984000_14.1.e013396.79","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.3390\/cancers14174160","article-title":"Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026011207400984000_14.1.e013396.80","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.ejcskn.2025.100624","article-title":"Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor\u2013naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A","volume":"3","author":"Gogas","year":"2025","journal-title":"EJC Skin Cancer"},{"key":"2026011207400984000_14.1.e013396.81","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"},{"key":"2026011207400984000_14.1.e013396.82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12672-024-01410-5","article-title":"Advances and prospects in tumor infiltrating lymphocyte therapy","volume":"15","author":"Qiu","year":"2024","journal-title":"Discov Onc"},{"key":"2026011207400984000_14.1.e013396.83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612"},{"key":"2026011207400984000_14.1.e013396.84","doi-asserted-by":"crossref","unstructured":"Huang H , Nie C , Liu X , et al . Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer. J Clin Invest 2022;132. doi:10.1172\/JCI157726","DOI":"10.1172\/JCI157726"},{"key":"2026011207400984000_14.1.e013396.85","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026011207400984000_14.1.e013396.86","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CJI.0000000000000355","article-title":"Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function","volume":"44","author":"Mullinax","year":"2021","journal-title":"J Immunother"},{"key":"2026011207400984000_14.1.e013396.87","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/cancers14030548","article-title":"Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma","volume":"14","author":"Ko","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026011207400984000_14.1.e013396.88","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7890985","article-title":"Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma","volume":"2020","author":"Zhou","year":"2020","journal-title":"J Immunol Res"},{"key":"2026011207400984000_14.1.e013396.89","first-page":"641","article-title":"Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy","volume":"12","author":"Shi","year":"2020","journal-title":"Immunotherapy (Los Angel)"},{"key":"2026011207400984000_14.1.e013396.90","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.jbo.2020.100332","article-title":"Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma","volume":"25","author":"Wang","year":"2020","journal-title":"J Bone Oncol"},{"key":"2026011207400984000_14.1.e013396.91","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00413-7"},{"key":"2026011207400984000_14.1.e013396.92","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"2026011207400984000_14.1.e013396.93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00167"},{"key":"2026011207400984000_14.1.e013396.94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.896228","article-title":"All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity","volume":"13","author":"Ram\u00edrez-Labrada","year":"2022","journal-title":"Front Immunol"},{"key":"2026011207400984000_14.1.e013396.95","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.3390\/cancers12123719","article-title":"Prospects for NK Cell Therapy of Sarcoma","volume":"12","author":"Lachota","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026011207400984000_14.1.e013396.96","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.986"},{"key":"2026011207400984000_14.1.e013396.97","doi-asserted-by":"crossref","first-page":"01","DOI":"10.31579\/2640-1053\/126","article-title":"Durable Responses Using SNK01 Autologous Enhanced Natural Killer Cells and Pembrolizumab for Chemotherapy-Resistant Advanced Sarcoma: Case Reports, Review of Literature and Future Perspectives","volume":"6","author":"M. Gordon","year":"2022","journal-title":"JCRCT"},{"key":"2026011207400984000_14.1.e013396.98","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026011207400984000_14.1.e013396.99","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129319","article-title":"FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies","volume":"134","author":"Goodridge","year":"2019","journal-title":"Blood"},{"key":"2026011207400984000_14.1.e013396.100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"2026011207400984000_14.1.e013396.101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41419-025-07443-0","article-title":"Engineered mesenchymal stem\/stromal cells against cancer","volume":"16","author":"Shi","year":"2025","journal-title":"Cell Death Dis"},{"key":"2026011207400984000_14.1.e013396.102","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10214","article-title":"Cell therapies in the clinic","volume":"6","author":"Wang","year":"2021","journal-title":"Bioengineering & Transla Med"},{"key":"2026011207400984000_14.1.e013396.103","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03183-1"},{"key":"2026011207400984000_14.1.e013396.104","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100231","article-title":"Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice","volume":"16","author":"Stamatopoulos","year":"2019","journal-title":"J Bone Oncol"},{"key":"2026011207400984000_14.1.e013396.105","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.SABCS-4134"},{"key":"2026011207400984000_14.1.e013396.106","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00018-015-1918-y","article-title":"Bone microenvironment signals in osteosarcoma development","volume":"72","author":"Alfranca","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"2026011207400984000_14.1.e013396.107","first-page":"354","article-title":"Osteoimmunology in bone malignancies: a symphony with evil","volume":"4","author":"Song","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"2026011207400984000_14.1.e013396.108","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4024"},{"key":"2026011207400984000_14.1.e013396.109","first-page":"4066","article-title":"Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells","volume":"61","author":"Lafleur","year":"2001","journal-title":"Cancer Res"},{"key":"2026011207400984000_14.1.e013396.110","doi-asserted-by":"crossref","unstructured":"Hawkins ER , D\u2019Souza RR , Klampatsa A . n.d. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. BTT Volume 15:95\u2013105. doi:10.2147\/BTT.S291768","DOI":"10.2147\/BTT.S291768"},{"key":"2026011207400984000_14.1.e013396.111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021"},{"key":"2026011207400984000_14.1.e013396.112","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/1078-0432.CCR-23-3298","article-title":"Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models","volume":"30","author":"Talbot","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026011207400984000_14.1.e013396.113","doi-asserted-by":"crossref","first-page":"1462076","DOI":"10.3389\/fimmu.2024.1462076","article-title":"A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma","volume":"15","author":"Hui","year":"2024","journal-title":"Front Immunol"},{"key":"2026011207400984000_14.1.e013396.114","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2026011207400984000_14.1.e013396.115","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00655-2"},{"key":"2026011207400984000_14.1.e013396.116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy","volume":"9","author":"He","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026011207400984000_14.1.e013396.117","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ymthe.2022.02.012","article-title":"Multipurposing CARs: Same engine, different vehicles","volume":"30","author":"Hossian","year":"2022","journal-title":"Mol Ther"},{"key":"2026011207400984000_14.1.e013396.118","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423167","article-title":"CD44v6 as innovative sarcoma target for CAR-redirected CIK cells","volume":"7","author":"Leuci","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026011207400984000_14.1.e013396.119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0357"},{"key":"2026011207400984000_14.1.e013396.120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol Rev"},{"key":"2026011207400984000_14.1.e013396.121","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-023-00534-0","article-title":"Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges","volume":"11","author":"Pang","year":"2023","journal-title":"Biomark Res"},{"key":"2026011207400984000_14.1.e013396.122","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026011207400984000_14.1.e013396.123","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1025"},{"key":"2026011207400984000_14.1.e013396.124","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026011207400984000_14.1.e013396.125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005065","article-title":"Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity","volume":"10","author":"Tang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026011207400984000_14.1.e013396.126","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2290900","article-title":"LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma","volume":"13","author":"Nielsen","year":"2024","journal-title":"Oncoimmunology"},{"key":"2026011207400984000_14.1.e013396.127","doi-asserted-by":"crossref","first-page":"101136","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: Focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev"},{"key":"2026011207400984000_14.1.e013396.128","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026011207400984000_14.1.e013396.129","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01981-8"},{"key":"2026011207400984000_14.1.e013396.130","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1016\/S1470-2045(24)00736-8","article-title":"New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis","volume":"26","author":"Pearson","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026011207400984000_14.1.e013396.131","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2025.200980","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"2026011207400984000_14.1.e013396.132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0832"},{"key":"2026011207400984000_14.1.e013396.133","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103645","article-title":"Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma","volume":"9","author":"Dufresne","year":"2024","journal-title":"ESMO Open"},{"key":"2026011207400984000_14.1.e013396.134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008450","article-title":"Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy","volume":"12","author":"Zou","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026011207400984000_14.1.e013396.135","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56486-6","article-title":"Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma","volume":"16","author":"Hosoya","year":"2025","journal-title":"Nat Commun"},{"key":"2026011207400984000_14.1.e013396.136","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8"},{"key":"2026011207400984000_14.1.e013396.137","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2140534","article-title":"Combined targeting of soluble latent TGF-\u00df and a solid tumor-associated antigen with adapter CAR T cells","volume":"11","author":"Werchau","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026011207400984000_14.1.e013396.138","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2024.200868","article-title":"Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer","volume":"32","author":"Lin","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"2026011207400984000_14.1.e013396.139","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.101994","article-title":"Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies","volume":"6","author":"Lopez","year":"2025","journal-title":"Cell Rep Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:40:34Z","timestamp":1768232434000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,12]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-013396"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013396","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}